Dr. Reddy's Laboratories announces the launch of Doxercalciferol Injection
Dr. Reddy's has launched Doxercalciferol Injection, 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, a therapeutic generic equivalent of Hectorol (doxercalciferol) Injection 4 mcg/2 ml (2 mcg/ml) multiple-dose vials, which has been approved by the U.S. Food and Drug Administration (USFDA).
Doxercalciferol, the active ingredient is a synthetic vitamin D2 analog that undergoes metabolic activation. Doxercalciferol Injectionis indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
According to IQVIA Health, the Hectorol Injection 4 mcg/2 ml (2 mcg/ml) single-dose vials and multiple-dose vials brand and generics had the sales of approximately US$138 mn MAT in the U.S for the most recent twelve months ending in September 2019. Hectorol is a trademark of Sanofi-Aventis US LLC.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, which provides affordable and innovative medicines for healthier lives. The company offers a portfolio of products and services, including APls, custom pharmaceutical services, generics, biosimilars, and differentiated formulations through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
On Friday, the stock of the company closed at Rs. 2,866, down by 0.43 per cent or Rs. 12.35 per share. The 52-week high is Rs. 2,965.20 and 52-week low is Rs. 2,065.30 on BSE.